DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 525-535

  Berghauser Pont, Lotte M E ^a   Naipal, Kishan ^b   Kloezeman, Jenneke J ^a   Venkatesan, Subramanian ^a   van den Bent, Martin ^b   van Gent, Dik C ^b   Dirven, Clemens M F ^a   Kanaar, Roland ^b   Lamfers, Martine L M ^a   Leenstra, Sieger ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c Department of Neurosurgery Elizabeth Medical Hospital   (Netherlands)

Author keywords

Bcl XL; Chek2; Glioblastoma; HDAC inhibitors; Radiation

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ATM PROTEIN; CASPASE 3; CASPASE 7; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; HISTONE H3; PANOBINOSTAT; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; TEMOZOLOMIDE; VALPROIC ACID; VORINOSTAT; APOPTOSIS REGULATORY PROTEIN; HYDROXAMIC ACID; INDOLE DERIVATIVE; RADIOSENSITIZING AGENT;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CELL LINE; CANCER MODEL; CELL FUNCTION; CLINICAL ARTICLE; DNA DAMAGE RESPONSE; DNA REPAIR; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; MALE; PREDICTION; PREDICTIVE VALUE; RADIOSENSITIZATION; ACETYLATION; ADULT; AGED; APOPTOSIS; CELL PROLIFERATION; DNA DAMAGE; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL CULTURE; VERY ELDERLY; WESTERN BLOTTING;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL PROLIFERATION; DNA DAMAGE; FEMALE; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; INDOLES; MALE; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 84919460146     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.049     Document Type: Article

References (40)

1. DeAngelis L.M. Brain tumors. N. Engl. J. Med 2001, 344:114-123.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med 2005, 352:987-996.
3. Stiborova M., Eckschlager T., Poljakova J., Hrabeta J., Adam V., Kizek R., et al. The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr. Med. Chem 2012, 19:4218-4238.
4. Shabason J.E., Tofilon P.J., Camphausen K. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J. Cell. Mol. Med 2011, 15:2735-2744.
5. Thiemann M., Oertel S., Ehemann V., Weichert W., Stenzinger A., Bischof M., et al. In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Radiat. Oncol 2012, 7:52.
6. Deorukhkar A., Shentu S., Park H.C., Diagaradjane P., Puduvalli V., Aggarwal B., et al. Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas 2010, 39:1277-1283.
7. Sonnemann J., Kumar K.S., Heesch S., Muller C., Hartwig C., Maass M., et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int. J. Oncol 2006, 28:755-766.
8. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys 2005, 62:223-229.
9. Groselj B., Kerr M., Kiltie A.E. Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. Radiother. Oncol 2013, 108:429-433.
10. Geng L., Cuneo K.C., Fu A., Tu T., Atadja P.W., Hallahan D.E. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006, 66:11298-11304.
11. U.S. National Institutes of Health, accessed 14.05.31. http://www.clinicaltrials.gov.
12. Balvers R.K., Kleijn A., Kloezeman J.J., French P.J., Kremer A., van den Bent M.J., et al. Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules. Neuro-Oncol 2013, 15:1684-1695.
13. Lee J.H., Choy M.L., Marks P.A. Mechanisms of resistance to histone deacetylase inhibitors. Adv. Cancer Res 2012, 116:39-86.
14. Emanuele S., Lauricella M., Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int. J. Oncol 2008, 33:637-646.
15. Groselj B., Sharma N.L., Hamdy F.C., Kerr M., Kiltie A.E. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br. J. Cancer 2013, 108:748-754.
16. Xu J., Sampath D., Lang F.F., Prabhu S., Rao G., Fuller G.N., et al. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J. Neurooncol 2011, 105:241-251.
17. Sims J.T., Plattner R. MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines. Cancer Chemother. Pharmacol 2009, 64:629-633.
18. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul 1984, 22:27-55.
19. Cen H., Mao F., Aronchik I., Fuentes R.J., Firestone G.L. DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells. FASEB J. 2008, 22:2243-2252.
20. Thon J.N., Devine M.T., Jurak Begonja A., Tibbitts J., Italiano J.E. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012, 120:1975-1984.
21. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev 2006, 58:621-681.
22. Coe R. What effect size is and why it is important accessed 14.09.26. http://www.leeds.ac.uk/educol/documents/00002182.htm.
23. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
24. Camphausen K., Burgan W., Cerra M., Oswald K.A., Trepel J.B., Lee M.J., et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004, 64:316-321.
25. Cha H., Lowe J.M., Li H., Lee J.S., Belova G.I., Bulavin D.V., et al. Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response. Cancer Res 2010, 70:4112-4122.
26. Peddi P., Loftin C.W., Dickey J.S., Hair J.M., Burns K.J., Aziz K., et al. DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells. Free Radic. Biol. Med 2010, 48:1435-1443.
27. Sallinen S.L., Ikonen T., Haapasalo H., Schleutker J. CHEK2 mutations in primary glioblastomas. J. Neurooncol 2005, 74:93-95.
28. Knappskog S., Chrisanthar R., Lokkevik E., Anker G., Ostenstad B., Lundgren S., et al. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 2012, 14:R47.
29. Chen X., Wong P., Radany E., Wong J.Y. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother. Radiopharm 2009, 24:689-699.
30. Okuno S., Shimizu S., Ito T., Nomura M., Hamada E., Tsujimoto Y., et al. Bcl-2 prevents caspase-independent cell death. J. Biol. Chem 1998, 273:34272-34277.
31. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov 2006, 5:769-784.
32. Watters D. Molecular mechanisms of ionizing radiation-induced apoptosis. Immunol. Cell Biol 1999, 77:263-271.
33. Wang J., Beauchemin M., Bertrand R. Bcl-xL phosphorylation at Ser49 by polo kinase 3 during cell cycle progression and checkpoints. Cell. Signal 2011, 23:2030-2038.
34. Kumar T.S., Kari V., Choudhary B., Nambiar M., Akila T.S., Raghavan S.C. Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J. Biol. Chem 2010, 285:32657-32670.
35. Jamil S., Stoica C., Hackett T.L., Duronio V. MCL-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle 2010, 9:2843-2855.
36. Gui C.Y., Ngo L., Xu W.S., Richon V.M., Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:1241-1246.
37. Camphausen K., Cerna D., Scott T., Sproull M., Burgan W.E., Cerra M.A., et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer 2005, 114:380-386.
38. Chinnaiyan P., Cerna D., Burgan W.E., Beam K., Williams E.S., Camphausen K., et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin. Cancer Res 2008, 14:5410-5415.
39. Munshi A., Tanaka T., Hobbs M.L., Tucker S.L., Richon V.M., Meyn R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther 2006, 5:1967-1974.
40. Chen X., Wong P., Radany E.H., Stark J.M., Laulier C., Wong J.Y. Suberoylanilide hydroxamic acid as radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol. Cancer Res 2012, 10:1052-1064.